2型糖尿病治療の新展開

出版社： 先端医学社
著者：
発行日： 2014-03-01
分野： 臨床医学：内科  >  糖尿病
ISBN： 9784884079598
電子書籍版： 2014-03-01 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

2,860 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,430 円(税込)

購入する

商品紹介

新規糖尿病治療薬「SGLT2 阻害薬」の可能性を多角度からコンパクトに解説する医療者必携の一冊。

目次

  • 2型糖尿病治療の新展開

    ―目次―

    PART 1　ナトリウム依存性グルコース輸送体（SGLT）の基礎を知る
    PART 2　SGLT2阻害薬の開発の経緯をみる
    PART 3　SGLT2阻害薬の基礎データをみる
    PART 4　SGLT2阻害薬の臨床データをみる
    PART 5　SGLT2阻害薬の特徴を知る
    PART 6　2型糖尿病治療におけるSGLT2阻害薬の位置づけを探る
    PART 7　SGLT2阻害薬に関する臨床応用Q & A　

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

PART 1 ナトリウム依存性グルコース輸送体 ( SGLT ) の基礎を知る

P.17 掲載の参考文献
1) 金井好克 : 糖の動態と代謝 腎尿細管における糖輸送. 日本臨牀 55 (増刊 糖尿病 1) : 59-64, 1997
 
2) 金井好克 : 糖尿病基礎研究の進歩 糖代謝概論 腎尿細管における糖輸送の分子機構. 日本臨牀 60 (増刊7 新時代の糖尿病学 1) : 141-150, 2002
 
3) 大久保博史, 中津祐介, 浅野知一郎 : 糖尿病治療の分子標的としてのグルコーストランスポーター, 細胞工学 31 : 548-552, 2012
Medical*Online
4) 大谷裕一郎, 浅野知一郎 : SGLT2阻害薬. カレントテラピー 30 : 670-674, 2012
Medical*Online
5) Wright EM, Loo DD, Hirayama BA : Biology of human sodium glucose transporters. Physiol Rev 91 : 733-794, 2011
PubMed
6) Hediger MA, Coady MJ, Ikeda TS et al : Expression cloning and cDNA sequencing of the Na+/glucose co-transporter. Nature 330 : 379-381, 1987
PubMed
7) Turk E, Kerner CJ, Lostao MP et al : Membrane topology of the human Na+/glucose cotransporter SGLT1. J Biol Chem 271 : 1925-1934, 1996
PubMed
8) Gok E Aydin HI, Kurt I et al : A novel mutation of Na+/glucose cotransporter in a Turkish newborn with congenital glucose-galactose malabsorption. J Pediatr Gastroenterol Nutr 40 : 508-511, 2005
 
9) Kanai Y, Lee WS, You G et al : The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 93 : 397-404, 1994
PubMed
10) Calado J, Loeffler J, Sakallioglu O et al : Familial renal glucosuria : SLCsA2 mutation analysis and evidence of salt-wasting. Kidney Int 69 : 852-855, 2006
PubMed
11) Tahrani AA, Bailey CJ, Del Prato S et al : Management of type 2 diabetes : new and future developments in treatment. Lancet 378 : 182-197, 2011
PubMed
12) Mitrakou A : Kidney : its impact on glucose homeostasis and hormonal regulation. Diabetes Res Clin Pract 93 Suppl 1 : S66-S72, 2011
 

PART 2 SGLT2阻害薬の開発の経緯をみる

P.27 掲載の参考文献
1) Oku A, Ueta K, Arakawa K et al : T-1095, an inhibitor of renal Na+ -glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48 : 1794-1800, 1999
PubMed
2) Ehrenkranz JR, Lewis NG, Kahn CR et al : Phlorizin : a review. Diabetes Metab Res Rev 21 : 31-38, 2005
PubMed
3) Alvarado F, Crane RK : Phlorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine, in vitro. Biochim Biophys Acta 56 : 170-172, 1962
PubMed
4) Vick H, Diedrich DF, Baumann K : Reevaluation of renal tubular glucose transport inhibition by phlorizin analogs. Am J Physiol 224 : 552-557, 1973
PubMed
5) Rossetti L, Smith D, Shulman GI et al : Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 79 : 1510-1515, 1987
PubMed
6) Rossetti L, Shulman GI, Zawalich W et al : Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 80 : 1037-1044, 1987
PubMed
7) Turk E, Zabel B, Mundlos S et al : Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter. Nature 350 : 354-356, 1991
PubMed
8) Gok E Aydin HI, Kurt I et al : A novel mutation of Na+/glucose cotransporter in a Turkish newborn with congenital glucose-galactose malabsorption. J Pediatr Gastroenterol Nutr 40 : 508-511, 2005
 
9) YU AS, Hirayama BA, Timbol G et al : Functional expression of SGLTs in rat brain. Am J Physiol Cill Physiol 299 : C1277-C1284, 2010
 
10) Oku A, Ueta K, Nawano M et at : Antidiabetic effect of T-1095, an inhibitor of Na (+) -glucose cotransporter, in neonatally streptozotocintreated rats. Eur J Pharmacol 391 : 183-192, 2000
 
11) Bailey CJ, Gross JL, Pieters A et al : Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin : a randomised, double-blind, placebo-controlled trial. Lancet 375 : 2223-2233, 2010
PubMed
12) Strojek K, Yoon KH, Hruba V et al : Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride : a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 13 : 928-938, 2011
PubMed
13) Bailey CJ, Iqbal N, Tjoen C et al : Dapagliflozin monotherapy in drugnaive patients with diabetes : a randomized-controlled trial of low-dose range. Diabetes Obes Metab 14 : 951-959, 2012
 
14) Devineni D, Morrow L, Hompesch M et al : Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 14 : 539-545, 2012
 
15) Rosenstock J, Aggarwal N, Polidori D et al : Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 35 : 1232-1238, 2012
PubMed
16) Nicolle LE, Capuano G, Ways K et al : Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin 28 : 1167-1171, 2012
 

PART 3 SGLT2阻害薬の基礎データをみる

P.42 掲載の参考文献
1) Mather A, Pollock C : Glucose handling by the kidney. Kidney Int Suppl 120 : S1-S6, 2011
PubMed
2) DeFronzo RA, Davidson JA, Del Prato S : The role of the kidneys in glucose homeostasis : a new path towards normalizing glycaemia. Diabetes Obes Metab 14 : 5-14, 2012
PubMed
3) Kasichayanula S, Chang M, Hasegawa M et al : Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab 13 : 357-365, 2011
PubMed
4) Kasichayanula S, Liu X, Shyu WC et al : Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab 13 : 47-54, 2011
PubMed
5) Smulders RA, Zhang W, Veltkamp SA et al : No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. Diabetes Obes Metab 14 : 937-943, 2012
PubMed
6) Suzuki M, Honda K, Fukazawa M et al : Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacot Exp Ther 341 : 692-701, 2012
 
7) 門脇孝, 窪田直人, 小畑淳史 : 新規血糖降下薬SGLT2阻害薬のこれからの糖尿病治療における位置づけ. Ther Res 34 : 1429-1440, 2013
Medical*Online
8) Yamaguchi K, Kato M, Suzuki M et al : In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat : a pharmacokinetic and pharmacodynamic modeling approach. J Pharmacol Exp Ther 345 : 52-61, 2013
 
9) Defronzo RA, Hompesch M, Kasichayanula S et al : Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 36 : 3169-3176, 2013
PubMed
10) Bolinder J, Ljunggren O, Kullberg J et al : Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97 : 1020-1031, 2012
PubMed
11) Bailey CJ, Iqbal N, Tjoen C et al : Dapagliflozin monotherapy in drug naive patients with diabetes : a randomized-controlled trial of low-dose range. Diabetes Obes Metab 14 : 951-959, 2012
 
12) Bailey CJ, Gross JL, Pieters A et al : Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin : a randomised, double-blind, placebo-controlled trial. Lancet 375 : 2223-2233, 2010
PubMed
13) Strojek K, YOon KH, Hruba V et al : Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride : a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 13 : 928-938, 2011
PubMed

PART 4 SGLT2阻害薬の臨床データをみる

P.57 掲載の参考文献
1) Bailey CJ, Iqbal N, Tjoen C et al : Dapagliflozin monotherapy in drug-naive patients with diabetes : a randomized-controlled trial of low-dose range. Diabetes Obes Metab 14 : 951-959, 2012
PubMed
2) Bailey CJ, Gross JL, Hennicken D et al : Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin : a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 11 : 43, 2013
PubMed
3) Kaku K et al : Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise. ADA2013, #1163-P
 
4) Inagaki N, Kondo K, Yoshinari T et al : Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes : A randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab 15 : 1136-1145, 2013
PubMed
5) 加来浩平, 高野泰樹, 池谷泰明ほか : 新規SGLT2阻害薬Tofoglifiozinの日本人2型糖尿病患者における有効性及び安全性の検証-第II/III相臨床試験結果. 第56回日本糖尿病学会年次学術集会, 熊本, 5月16-18日, 2013
 
6) Kashiwagi A, Takinami Y, Kazuta K et al : Ipragliflozin improved glycaemic control with additional benefits of reductions of body weight and blood pressure in Japanese patients with type 2 diabetes mellitus : BRIGHTEN Study EASD2011, #149
 
7) Haneda M et al : Empagliflozin monotherapy for 12 weeks improves glycemic control in Japanese patients with type 2 diabetes (T2DM). ADA2013, #1144-P
 
8) Seino Y, Sasaki T, Fukatsu A et al : Luseogliflozin (TS-071), aselective SGLT21nhibitor, improves glycemic control and lowers body weight in Japanese patients with type 2 diabetes mellitus. ADA2013, #1039P
 
9) Tanizawa Y, Kaku K, Araki E et at : Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus : multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother 2014 in press
 
10) Wilding JP, Woo V, Soler NG et al : Long-term efficacy of dapagliflozin in patients With type 2 diabetes mellitus receiving high doses of insulin : a randomized trial. Ann Intern Med 156 : 405-415, 2012
PubMed
11) Kaku K, Inoue S, Matsuoka O et al : Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control : a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 15 : 432-440, 2013
PubMed
12) Johnsson KM, Ptaszynska A, Schmitz B et al : Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 27 : 473-478, 2013
PubMed
13) Johnsson KM, Ptaszynska A, Schmitz B et al : Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 27 : 479-484, 2013
PubMed
14) Food and Drug Administration. FDA Briefing Document NDA 202293. Dapagliflozin 5 and 10mg. 2011. http://www.fda.gov/downloads/AdvisoryCommittees/Committees-MeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM262994.pdf
 
15) Food and Drug Administration. FDA Briefing Document NDA 204042. Invokana (canagliflozin) tablets. Food and Drug Administration, 2013. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf
 

PART 5 SGLT2阻害薬の特徴を知る

P.74 掲載の参考文献
1) Kaku K et al : Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise. ADA2013, #1163-P
 
2) Inagaki N, Kondo K, Yoshinari T et al : Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes : A randomized, dollble-blind, placebo-controlled, 12-week study. Diabetes Obes Metab 15 : 1136-1145, 2013
PubMed
3) Kashiwagi A, Takinami Y, Kazuta K et al : Ipragliflozin improved glycaemic control with additional benefits of reductions of body weight and blood pressure in Japanese patients with type 2 diabetes mellitus : BRIGHTEN Study EASD2011, #149
 
4) 加来浩平, 高野泰樹, 池谷泰明ほか : 新規SGLT2阻害薬Tofogliflozinの日本人2型糖尿病患者における有効性及び安全性の検証-第II/III相臨床試験結果, 第56回日本糖尿病学会年次学術集会, 熊本, 5月16-18日, 2013
 
5) Haneda M et al : Empagliflozin monotherapy for 12 weeks improves glycemic control in Japanese patients with type 2 diabetes (T2DM). ADA2013, #1144-P
 
6) Seino Y, Sasaki T, Fukatsu A et al : Luseoglifiozin (TS-071), a selective SGLT2 inhibitor, improves glycemic control and lowers body weight in Japanese patients with type 2 diabetes mellitus. ADA2013, #1039P
 
7) Fonseca VA, Ferrannini E, Wilding JP et al : Active-and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complications 27 : 268-273, 2013
PubMed
8) Henry RR, Murray AV, Marmolejo MH et al : Dapagliflozin, metformin XR, or both : initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 66 : 446-456, 2012
PubMed
9) Cefalu WT, Leiter LA, Yoon KH et al : Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU) : 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382 : 941-950, 2013
PubMed
10) Nauck M, Del Prato S, Rohwedder K et al : Long-term efficacy and safety of add-on dapagliflozin vs add-on glipizide in patients with T2DM inadequately controlled with metformin : 2-year results. ADA2011, #40-LB
 
11) Lavalle-Gonzalez FJ, Januszewicz A Davidson J et al : Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy : a randomised trial. Diabetologia 56 : 2582-2592, 2013
PubMed
12) Schernthaner G, Gross JL, Rosenstock J et al : Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea : A 52-week randomized trial. Diabetes Care 36 : 2508-2515, 2013
 
13) Kasichayanula S, Chang M, Hasegawa M et al : Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab 13 : 357-365, 2011
PubMed
14) Bailey CJ, Iqbal N, Tjoen C et al : Dapagliflozin monotherapy in drug-naive patients with diabetes : a randomized-controlled trial of low-dose range. Diabetes Obes. Metab 14 : 951-959, 2012
 
15) Bailey CJ, Gross JL, Pieters A et al : Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin : a randomised, double-blind, placebo-controlled trial. Lancet 375 : 2223-2233, 2010
PubMed
16) Strojek K Ybon KH, Hruba V et al : Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride : a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes. Metab 13 : 928-938, 2011
 
17) Sten16f K, Cefalu WT, Kim KA et al : Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15 : 372-382, 2013
 
18) Suzuki M, Honda K, Fukazawa M et al : Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther 341 : 692-701, 2012
PubMed
19) Sarashina A, Koiwai K, Seman LJ et al : Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet 28 : 213-219, 2013
PubMed
20) Ferrannini E, Seman L, Seewaldt-Becker E et al : A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 15 : 721-728, 2013
PubMed

PART 6 2型糖尿病治療におけるSGLT2阻害薬の位置づけを探る

P.85 掲載の参考文献
1) 糖尿病治療ガイド 2012-2013, 日本糖尿病学会編, 文光堂, 東京, 2013
 
2) 岩本安彦, 川田祐一郎, 弘世貴久ほか : 糖尿病治療の新展開-インクレチン関連薬, 特にDPP-4阻害薬の可能性-. Prog Med 30 : 2181-2188, 2010
 
3) Bonds DE, Miller ME, Bergenstal RM et al : The association between symptomatic, scvere hypoglycaemia and mortality in type 2 diabetes : retrospective epidemiological analysis of the ACCORD study. BMJ 340 : b4909, 2010
PubMed
4) Kaku K et al : Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise. ADA2013, #1163-P
 
5) Inagaki N, Kondo K, Yoshinari T et al : Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes : A randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab 15 : 1136-1145, 2013
PubMed
6) Kashiwagi A, Takinami Y, Kazuta K et al : Ipragliflozin improved glycaemic control with additional benefits of reductions of body weight and blood pressure in Japanese patients with type 2 diabetes mellitus : BRIGHTEN Study EASD2011, #149
 
7) 加来浩平. 高野泰樹, 池谷泰明ほか : 新規SGLT2阻害薬Tofogliflozinの日本人2型糖尿病患者における有効性及び安全性の検証-第II/III相臨床試験結果. 第56回日本糖尿病学会年次学術集会, 熊本, 5月16-18日, 2013
 
8) Haneda M et al : Empagliflozin monotherapy for 12 weeks improves glycemic control in Japanese patients with type 2 diabetes (T2DM). ADA2013, #1144-P
 
9) Seino Y, Sasaki T, Fukatsu A et al : Luseogliflozin (TS-071), a selective SGLT2 inhibitor, improves glycemic control and lowers body weight in Japanese patients with type 2 diabetes mellitus. ADA2013, #1039P
 
10) Bailey CJ, Gross JL, Hennicken D et al : Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin : a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 11 : 43, 2013
PubMed
11) Henry RR, Murray AV, Marmolejo MH et al : Dapagliflozin, metformin XR, or both : initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 66 : 446-456, 2012
PubMed
12) Lavalle-Gonzalez FJ, Januszewicz A, Davidson J et al : Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy : arandomised trial. Diabetologia 56 : 2582-2592, 2013
PubMed
13) Nauck M, Del Prato S, Rohwedder K et al : Long-term efficacy and safety of add-on dapagliflozin vs add-on glipizide in patients with T2DM inadequately controlled with metformin : 2-year results. ADA2011, #40-LB
 
P.96 掲載の参考文献
1) 糖尿病治療ガイド 2012-2013, 日本糖尿病学会編, 文光堂, 東京, 2013
 
2) Henry RR, Murray AV, Marmolejo MH et al : Dapagliflozin, metformin XR, or both : initial pharmacotherapy for type 2 diabetes. a randomised controlled trial. Int J Clin Pract 66 : 446-456, 2012
PubMed
3) Nauck MA Del Prato S, Meier JJ et al : Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin : a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34 : 2015-2022, 2011
 
4) Strojek K, Yoon KH, Hruba V et al : Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride : arandomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 13 : 928-938, 2011
 
5) Wilding JP, Woo V, Soler NG et al : Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin : a randomized trial. Ann Intern Med 156 : 405-415, 2012
 
6) Tanizawa Y, Kaku K, Araki E et al : Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus : multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother 2014 in press
PubMed
P.104 掲載の参考文献
1) Mather A Pollock C : Glucose handling by the kidney. Kidney Int Suppl 120 : S1-S6, 2011
PubMed
2) DeFronzo RA, Davidson JA, Del Prato S : The role of the kidneys in glucose homeostasis : a new path towards normalizing glycaemia. Diabetes Obes Metab 14 : 5-14, 2012
PubMed
3) Kaku K et al : Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise. ADA2013, #1163-P
 
4) Inagaki N, Kondo K, Yoshinari T et al : Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes : a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab 15 : 1136-1145, 2013
PubMed
5) Kashiwagi A, Takinami Y, Kazuta K et al : Ipragliflozin improved glycaemic control with additional benefits of reductions of body weight and blood pressure in Japanese patients with type 2 diabetes mellitus : BRIGHTEN Study EASD2011, #149
 
6) 加来浩平, 高野泰樹, 池谷泰明ほか : 新規SGLT2阻害薬Tofogliflozinの日本人2型糖尿病患者における有効性及び安全性の検証-第II/III相臨床試験結. 果. 第56回日本糖尿病学会年次学術集会, 熊本, 5月16-18日, 2013
 
7) Haneda M et al : Empagliflozin monotherapy for 12 weeks improves glycemic control in Japanese patients with type 2 diabetes (T2DM). ADA2013, #1144-P
 
8) Seino Y, Sasaki T, Fukatsu A et al : Luseogliflozin (TS-071), a selective SGLT2 inhibitor, improves glycemic control and lowers body weight in Japanese patients with type 2 diabetes mellitus. ADMO13, #1039P
 
9) Henry RR, Murray AV, Marmolejo MH et al : Dapaglifiozin, metformin XR, or both : initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 66 : 446-456, 2012
PubMed
10) Schernthaner G, Gross JL, Rosenstock J et al : Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea : a 52-week randomized trial. Diabetes Care 36 : 2508-2515, 2013
 
11) Bolinder J, Ljung9ren O, Kullberg J et al : Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97 : 1020-1031, 2012
 
12) Bailey CJ, Iqbal N, Tjoen C et al : Dapagliflozin monotherapy in drug-naive patients with diabetes : a randomized-controlled trial of low-dose range. Diabetes Obes Metab 14 : 951-959, 2012
PubMed
13) Bailey CJ, Gross JL, Pieters A et al : Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin : a randomised, double-blind, placebo-controlled trial. Lancet 375 : 2223-2233, 2010
PubMed
14) 嶺尾郁夫 : 肥満・インスリン抵抗性と尿酸排泄. 高尿酸血症と痛風 17 : 39-45, 2009
Medical*Online
15) Matsuura F, Yamashita S, Nakamura T et al : Effect of visceral fat accumulation on uric acid metabolism in male obese subjects : visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism 47 : 929-933, 1998
PubMed
16) Macdonald FR, Peel JE, Jones HB et al : The novel sodium glucose transporter 2 inhibitor dapaglifiozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab 12 : 1004-1012, 2010
PubMed

書評

最近チェックした商品履歴

Loading...